Lizomac DS Dry Syrup contains Linezolid 100mg/5ml as its active ingredient and is an oxazolidinone class antibiotic indicated for the treatment of serious bacterial infections caused by susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). It is particularly effective in managing respiratory tract infections, skin and soft tissue infections, and complicated intra-abdominal infections. The dry syrup formulation allows for convenient reconstitution and administration in pediatric patients or those unable to swallow tablets. Linezolid acts by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. Lizomac DS Dry Syrup should be used under medical supervision with dosage adjusted according to the severity of infection and patient weight. Caution is advised in patients with a history of myelosuppression, serotonin syndrome, or those receiving serotonergic agents due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and reversible myelosuppression with prolonged use. Proper adherence to prescribed duration is essential to prevent resistance development. This medication is contraindicated in patients with hypersensitivity to linezolid or any excipients.